AACR 2025 | BlissBio to Present 4 ADC Posters at the 2025 AACR Annual Meeting

HONG KONG, China, April 28, 2025 – BlissBio announces today 4 posters of anti-tumor antibody-drug conjugate (ADC) preclinical study results will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 from April 25 to 30, 2025, in McComick Place Convention Center, Chicago, IL, U.S.

Abstract Title: Preclinical studies of BB-1709, a CD73-targeting ADC potentially suppresses tumor growth through dual mechanisms

Abstract #: 2243 / 14

Session Date and Time: 09:00 AM - 12:00 PM, April 28, 2025 (local time) 

Abstract Title: Preclinical studies of BR-2302: A HER3xEGFR bi-specific Exd-containing ADC

Abstract #: 3417 / 12

Session Date and Time: 02:00 PM - 05:00 PM, April 28, 2025 (local time)

Abstract Title: Preclinical studies of BB-1705: An EGFR-targeting eribulin-containing ADC with an affinity optimized antibody to minimize potential toxicities to normal tissues

Abstract #: 4779 / 15

Session Date and Time: 09:00 AM - 12:00 PM, April 29, 2025 (local time) 

Abstract Title: Preclinical studies of BB-1712: A B7H3-targeting eribulin-containing ADC with the potential to overcome resistance to DNA topoisomerase I inhibitor-containing ADCs

Abstract #: 6173 / 25

Session Date and Time: 02:00 PM - 05:00 PM, April 29, 2025 (local time)

Bliss Biopharmaceutical Co., Ltd

TEL: +86-0571-86808367

E-mail: office@blissbiopharma.com